LGR5 and neoplasm: These results suggest that elevated immunohistochemical expression of LGR5 does not contribute to the progression of the tumor, and it could not be used as a potential unfavorable prognostic biomarker for CRC; however, the strength of expression was increased with the stage of tumor; 50% of stage II, 55.56% of stage III, and 60% of stage IV.